ACRSAclaris Therapeutics, Inc.
$3.78+105% 1Y
$3.78
$1.8152 weeks$6.54
What is the market doing?
Mixed
1 neutral, 2 without dataRangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
TrendRangeboundderived · Oct 8, 2026
Rangebound, no clear trend. Oversold (RSI 28). Price is −15% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ACRS is trading
Aclaris Therapeutics, Inc. is +105% over the past year while the S&P 500 is +18%: 87 points ahead of the market.
+105%
1-year return · S&P 500 +18%
- vs 200-day average
- −15%
vs 200-day average · a clear downtrend
- RSI (14)
- 28
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 42%
Below its 52-week high
Details›
- Last close2026-10-08
- $3.78
- 1 monthS&P 500 +1.6%
- −32%
- 1 yearS&P 500 +18%
- +105%
- 5 yearsS&P 500 +86%
- −79%
- vs 50-day average$5.59
- −32%
- 52-week high
- $6.54
- 52-week low
- $1.81
- Annualised volatility
- 101%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$1.4M
| Year | Return |
|---|---|
| 2026 (year to date) | +26% |
| 2025 | +21% |
| 2024 | +136% |
| 2023 | −93% |
| 2022 | +8.3% |
| 2021 | +125% |
| 2020 | +242% |
| 2019 | −74% |
| 2018 | −70% |
| 2017 | −9.1% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +18% |
| Feb | 10 | 4 of 10 | −2.5% |
| Mar | 10 | 4 of 10 | −2.7% |
| Apr | 10 | 5 of 10 | +0.81% |
| May | 10 | 5 of 10 | −4.7% |
| Jun | 10 | 7 of 10 | +1.9% |
| Jul | 11 | 6 of 11 | +0.74% |
| Aug | 11 | 6 of 11 | −0.27% |
| Sep | 11 | 4 of 11 | +1.2% |
| Oct | 11 | 4 of 11 | +9.5% |
| Nov | 10 | 3 of 10 | +2.0% |
| Dec | 10 | 7 of 10 | +8.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.